Loading organizations...

Government funding program funding early-stage life sciences innovation, focused on therapeutics, diagnostics, and life science tools.
BMBF GO-Bio is not a company but a funding initiative established by the German Federal Ministry of Education and Research (BMBF). Its purpose is to support the transfer of research findings from life sciences into commercial applications, specifically by assisting academic researchers in developing innovative ideas toward company formation. The initiative provides financial backing and strategic guidance to bridge the gap between scientific discovery and market readiness, focusing on various stages from initial concept validation to the establishment of new biotechnology ventures.
Launched to foster entrepreneurship within the German life science sector, the program was conceived to address the challenge of commercializing promising scientific breakthroughs. While not founded by individuals in the traditional sense of a startup, its inception stems from the BMBF's strategic objective to strengthen Germany's position in biotechnology by incentivizing researchers to translate their work into tangible economic value and new companies. This governmental impetus provides a foundational structure for nurturing innovative projects.
The beneficiaries of GO-Bio are academic scientists and research teams with groundbreaking concepts in the life sciences, aiming to transform their work into viable businesses. The long-term vision of the initiative is to stimulate the creation of a dynamic ecosystem for life science startups in Germany, driving innovation, generating high-tech jobs, and ultimately bringing novel solutions to market that address critical health and environmental challenges.
BMBF GO-Bio has 1 tracked investment across 1 company. The latest tracked deal is $13.0M Seed in Seamless Therapeutics in March 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 1, 2023 | Seamless Therapeutics | $13.0M Seed | Forbion, Karl Nagler | — |